Chromosomal aberrations in human lymphocytes exposed in vitro to enrofloxacin and ciprofloxacin

Toxicology Letters

Volumn 104, Issue 1-2, 1999, Pages 43-48

  Gorla, N ^a   Garcia Ovando H ^a   Larripa, I ^b  

^a DEPARTAMENTO DE QUÍMICA   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Chromosomal aberrations; Ciprofloxacin; Enrofloxacin

Indexed keywords

CIPROFLOXACIN; ENROFLOXACIN;

ARTICLE; CELL CULTURE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOSE RESPONSE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTI-INFECTIVE AGENTS; CELLS, CULTURED; CHROMOSOME ABERRATIONS; CIPROFLOXACIN; FEMALE; FLUOROQUINOLONES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; QUINOLONES;

EID: 0032911202     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00230-6     Document Type: Article

References (21)

1. Anadón A., Martínez-Larrañaga M.R., Díaz J. et al. Pharmacokinetics and residues of enrofloxacin in chickens. Am. J. Vet. Res. 56:1995;501-506.
2. Barragry T.B. Current residue concern and tolerances. Barragry T.B. Veterinary Drug Therapy. 1994;355-381 Lea and Febiger, Philadelphia.
3. Basaran A., Erol K., Basaran N., Gunes H., Acikalin E., Timuralp G. Effects of ciprofloxacin on chromosomes, and hepatic and renal functions in rats. Chemotherapy. 39:1993;182-188.
4. Ciaravino V., Suto M.J., Theiss J.C. High capacity in vitro micronucleus assay for assessment of chromosome damage: results with quinolone/naphthyridone antibacterials. Mutat. Res. 298:1993;227-236.
5. Christ W., Lehnert T., Ulbrich B. Specific toxicologic aspects of the quinolones. Rev. Infect. Dis. 10:1988;603-606.
6. Evans H.J. Chromosomal mutations in human populations, Cytogenet. Cell Genet. 33:1982;48-56.
7. Grachech S.J., Mychajlonka M., Gambino L. et al. Correlations of quinolone inhibition endpoints versus bacterial DNA gyrase, mammalian topoisomerase I and II and cell clonogenic survival, and in vitro micronucleus induction. In program and abstracts of the Thirty-First conference on antimicrobial agents and chemotherapy, Chicago IL, Abstract 1438. 1991;American Society for Microbiology, Washington, DC.
8. Gorla N., Chiostri E., Ugnia L. et al. HPLC residues of enrofloxacin and ciprofloxacin in eggs of laying hens. Int. J. Antim. Agents. 8:1997;253-256.
9. Gorla N., Ledesma O.S., Barbieri G.P., Larripa I.B. Thirteenfold increase of chromosomal aberrations non- randomly distributed in chagasic children treated with Nifurtimox. Mutat. Res. 224:1989;263-267.
10. ISCN, 1985. An International System for Human Cytogenetic Nomenclature, S. Karger, New York.
11. Kung K., Riond J.L., Wanner M. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J. Vet. Pharmacol. Therap. 16:1993;462-468.
12. Kung K., Riond J.L., Wolffram S., Wanner M. Comparison of an HPLC and bioassay method to determine antimicrobial concentrations after intravenous and oral administration of enrofloxacin in four dogs. Res. Vet. Sci. 54:1993;247-248.
13. Larripa I., Carballo M., Mudry M., Labal de Vinuesa M. Etoposide and teniposide: In Vivo and In vitro genotoxic studies. Drug Invest. 4:1992;265-275.
14. Mitelman F., Kolning A.M., Strombeck B. et al. No cytogenetic effects of quinolone treatment in humans. Antimicrob. Agents Chemotheraphy. 32:1988;936-937.
15. Moorhead P.S., Nowell P., Mellman W.J., Battips W.J., Hungerford D.A. Chromosome preparation of leukocyte cultures from human peripheral blood. Exp. Cell Res. 20:1960;613-616.
16. Mukherjee A., Sen S., Agarwal K. Ciprofloxacin: Mammalian DNA topoisomerase type II poison in vivo. Mutat. Res. 301:1993;87-92.
17. Nordenson I., Beckman L., Liden S., Stjernberg N. Chromosomal aberrations and cancer risk. Hum. Hered. 34:1984;76-81.
18. Pino A. Induction of sperm abnormalities and dominant lethal effects in mice treated with ciprofloxacin. Med. Sci. Res. 23:1995;321-322.
19. Shimada H., Ebine Y., Kurosawa Y., Auruchi T. Mutagenicity studies of DL-8280, a new antibacterial drug. Chemotherapy. 32(S-1):1984;1162-1170.
20. Takayama S., Hirohashi M., Kato M., Shimada H. Toxicity of quinolone antimicrobial agents. J. Toxicol. Environ. Health. 45:1995;1-45.
21. Vancutsem P.M., Babish J.C., Schawark W.S. The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet. 201:1990;1388-1390.